Johnson and Johnson (JNJ) 시세

Johnson & Johnson seeks U.S. FDA approval for first pediatric indications for TREMFYA® (guselkumab)

Johnson & Johnson seeks U.S. FDA approval for first pediatric indications for TREMFYA® (guselkumab) PR Newswire SPRING HOUSE, Pa., Dec. 2, 2024 Applications filed for TREMFYA® to treat...

Johnson & Johnson seeks U.S. FDA approval for subcutaneous induction regimen of TREMFYA® (guselkumab) in ulcerative colitis, a first for an IL-23 inhibitor

Johnson & Johnson seeks U.S. FDA approval for subcutaneous induction regimen of TREMFYA® (guselkumab) in ulcerative colitis, a first for an IL-23 inhibitor PR Newswire SPRING HOUSE, Pa., Nov...

Johnson & Johnson to showcase strength of its broad hematology portfolio and pipeline at the 2024 American Society of Hematology Annual Meeting

Johnson & Johnson to showcase strength of its broad hematology portfolio and pipeline at the 2024 American Society of Hematology Annual Meeting PR Newswire RARITAN, N.J., Nov. 19, 2024 More...

Icotrokinra delivered an industry-leading combination of significant skin clearance with demonstrated tolerability in a once daily pill in Phase 3 topline results

Icotrokinra delivered an industry-leading combination of significant skin clearance with demonstrated tolerability in a once daily pill in Phase 3 topline results PR Newswire SPRING HOUSE, Pa...

Nipocalimab demonstrates significant clinical improvement in disease activity and IgG reduction in Phase 2 Sjögren's disease study

Nipocalimab demonstrates significant clinical improvement in disease activity and IgG reduction in Phase 2 Sjögren's disease study PR Newswire WASHINGTON, Nov. 14, 2024 Adults with...

Form 13F-HR - Quarterly report filed by institutional managers, Holdings

Nipocalimab is the first and only investigational therapy granted U.S. FDA Breakthrough Therapy Designation for the treatment of adults living with moderate-to-severe Sjögren's disease

Nipocalimab is the first and only investigational therapy granted U.S. FDA Breakthrough Therapy Designation for the treatment of adults living with moderate-to-severe Sjögren's disease PR...

Johnson & Johnson submits applications in the U.S. and EU seeking approval of DARZALEX FASPRO® / DARZALEX® as subcutaneous monotherapy for high-risk smoldering multiple myeloma

Johnson & Johnson submits applications in the U.S. and EU seeking approval of DARZALEX FASPRO® / DARZALEX® as subcutaneous monotherapy for high-risk smoldering multiple myeloma PR...

Johnson & Johnson advances leadership in rheumatic disease innovation with 43 abstracts at ACR 2024

Johnson & Johnson advances leadership in rheumatic disease innovation with 43 abstracts at ACR 2024 PR Newswire SPRING HOUSE, Pa., Nov. 7, 2024 New data for investigational nipocalimab in...